Hepatitis B
Conditions
Interventions
Experimental group: 50 individuals. Administration of hepatitis B vaccine, recombinant EUVAX B manufactured by LG Life Sciences Laboratory (Lot # WVX 16014), produced at KOREA. The doses of 1 ml will
Biological/vaccine
C23.550.340.500
Sponsors
Faculdade de Enfermagem Universidade Federal de Goiás
Fundação de Amparo à Pesquisa do Estado de Goiás
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Susceptible to infection by hepatitis B virus infection (anti-HBs marker alone); Being male; Age between 18 years; Prison regime in the Regional Prison of Itumbiara with penalty expected for more than eight months.
Exclusion criteria
Exclusion criteria: To present any clinical picture that contraindicates hepatitis B vaccination; Effect of substances that compromise the data response and the integrity of the researchers; Medical diagnosis of mental disorders; Present at the time of data collection behavior that endangers the physical and / or emotional health of the researcher. To present difficulty of understanding in order to respond to the instrument of data collection (auditory deficiency and / or altered speech).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum titre of quantitative anti-HBs antibodies (greater than 10 mIU / mL = protective titres) determined after the hepatitis B vaccination schedule is expected. Blood will be collected 30 to 45 days after the last dose of the vaccine and will be evaluated by the electrochemiluminescence assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| The level of pain less than 10 (worse pain) reported after the administration of each dose of the vaccine is expected using the analog pain scale;It is expected that the individual will not reattagenicity after each dose of hepatitis B vaccine given;It is expected that sex, age, obesity, smoking and autoimmune diseases alter titration response (less than 10 mIU / mL) after vaccination. The SPSS 13.0 program will be used | — |
Countries
Brazil
Contacts
Public ContactMarcos de Matos
Universidade Federal de Goiás
Outcome results
None listed